Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $97.55 USD
Change Today -0.80 / -0.81%
Volume 1.4M
NVS On Other Exchanges
Symbol
Exchange
Xetra
OTC US
Mexico
SIX Swiss Ex
SIX Swiss Ex
Frankfurt
As of 1:31 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Lichtstrasse 35

Basel, 4056

Switzerland

Phone: 41 61 324 11 11

Fax:

ing the U.S., the EU member states and Japan. Exjade is also approved in approximately 70 countries, including the U.S. and the EU member states, for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia. Femara (letrozole) is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Femara is available in approximately 90 countries. Femara is approved in the U.S., the EU member states and other countries in the adjuvant, extended adjuvant and neo-adjuvant (pre-operative) settings for early stage breast cancer. Femara is also approved in the U.S. and other countries as adjuvant therapy for locally advanced breast cancer and for advanced breast cancer following anti-estrogen therapy. Femara is approved as neo-adjuvant therapy for early stage breast cancer in a limited number of countries. In Japan, Femara is approved for the treatment of all hormone receptor-positive breast cancer in postmenopausal women. Jakavi (ruxolitinib) is an oral inhibitor of the JAK1 and JAK2 tyrosine kinases. It is a JAK inhibitor indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis. Jakavi is approved in approximately 65 countries, including the EU member states, Japan, Canada, Australia, Mexico and Argentina. Ruxolitinib, marketed in the U.S. as Jakafi by Incyte Corporation, was approved by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also approved by the FDA for treatment of patients with intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis. Zometa (zoledronic acid for injection/zoledronic acid 4 mg) is a treatment to reduce or delay skeletal-related events, including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Zometa is approved in approximately 100 countries for this indication, as well as for the treatment of patients with multiple myeloma and patients with bone metastasis from solid malignancies, including prostate, breast and lung cancer. Zoledronic acid, the active ingredient in Zometa, is also available under the trade names Reclast/Aclasta for use in non-oncology indications. Reclast/Aclasta is approved in 107 countries for the treatment of osteoporosis in postmenopausal women, osteoporosis in men, Paget's disease of bone and prevention of clinical fractures after hip fracture and for the treatment and prevention of glucocorticoid-induced osteoporosis. Zykadia (ceritinib) is an oral, selective inhibitor of ALK, an important therapeutic target in lung cancer. In 2014, Zykadia was granted accelerated approval by the FDA for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. Signifor (pasireotide) is a somatostatin analogue approved in approximately 65 countries, including countries of the EU, Switzerland and the U.S., for the treatment of adults with Cushing's disease for whom pituitary surgery is not an option or has not been curative. Cardio-Metabolic Galvus (vildagliptin), an oral DPP-4 inhibitor, and Eucreas, a single-pill combination of vildagliptin and metformin, are indicated for the treatment of type 2 diabetes. Galvus is approved in approximately 120 countries, including the EU member states, Japan and countries in Latin America and the Asia-Pacific. Eucreas was the first single pill combining a DPP-4 inhibitor and metformin that was approved in Europe and under the trade name Galvus Met is approved in approximately 100 countries. Immunology and Dermatology Neoral (

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NVS:US $97.55 USD -0.80

NVS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Gilead Sciences Inc $106.38 USD -1.40
Johnson & Johnson $94.31 USD -0.86
Merck & Co Inc $54.01 USD -1.36
Nestle SA SFr.71.30 CHF +0.40
Sanofi €88.17 EUR -0.27
View Industry Companies
 

Industry Analysis

NVS

Industry Average

Valuation NVS Industry Range
Price/Earnings 24.8x
Price/Sales 4.6x
Price/Book 3.0x
Price/Cash Flow 13.4x
TEV/Sales 4.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NOVARTIS AG-SPONSORED ADR, please visit www.novartis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.